ArticlemSystems2021
Indoor Dust as a Matrix for Surveillance of COVID-19.
Article in mSystems, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 59 citations in OpenAlex.
- Improving Inference from Reported Concentrations in Environmental Surveillance by Modeling the Statistical Features of Digital PCR.ACS ES&T water · 2026Article
- Simultaneous detection of multiple viral pathogens in vacuumed dust from different building types.Building and environment · 2026Article
- Microbiology of the Built Environment: Applying Our Knowledge for Healthy Indoor Spaces.Environmental science & technology · 2026Article
- Determining farm surface porcine reproductive and respiratory syndrome virus (PRRSV) contamination through viability RT-qPCR.PloS one · 2026Article
- Cleaning and Disinfecting Public Transportation Vehicles Against Respiratory Infectious Diseases in Lebanon: A Cross-Sectional Study.Risk management and healthcare policy · 2026Article
- Predicting COVID-19 Cases Across a Large University Campus Using Built Environment Surveillance.Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2024Article
- Moving beyond species: fungal function in house dust provides novel targets for potential indicators of mold growth in homes.Microbiome · 2024Article
- Genetic tracing of market wildlife and viruses at the epicenter of the COVID-19 pandemic.Cell · 2024Article
- Exploring indoor and outdoor dust as a potential tool for detection and monitoring of COVID-19 transmission.iScience · 2024Article
- Identification of SARS-CoV-2 variants in indoor dust.PloS one · 2024Article
- Methodologies for the collection of parameters to estimate dust/soil ingestion for young children.Frontiers in public health · 2024Article
- Genetic tracing of market wildlife and viruses at the epicenter of the COVID-19 pandemic.bioRxiv : the preprint server for biology · 2023Article
- Predicting COVID-19 cases using SARS-CoV-2 RNA in air, surface swab and wastewater samples.The Science of the total environment · 2023Article
- Municipal solid waste, an overlooked route of transmission for the severe acute respiratory syndrome coronavirus 2: a review.Environmental chemistry letters · 2023Review
- SARS-CoV-2 RNA Is Readily Detectable at Least 8 Months after Shedding in an Isolation Facility.mSphere · 2022Article
- Digital PCR Applications in the SARS-CoV-2/COVID-19 Era: a Roadmap for Future Outbreaks.Clinical microbiology reviews · 2022Review
- Article
- SARS-CoV-2 Surveillance in Indoor Air Using Electrochemical Sensor for Continuous Monitoring and Real-Time Alerts.Biosensors · 2022Article
- SARS-CoV-2 Distribution in Residential Housing Suggests Contact Deposition and Correlates withmSystems · 2022Article
- The Built Environment Assessment of Residential Areas in Wuhan during the Coronavirus Disease (COVID-19) Outbreak.International journal of environmental research and public health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ongoing disease surveillance is a critical tool to mitigate viral outbreaks, especially during a pandemic. Environmental monitoring has significant promise even following widespread vaccination among high-risk populations. The goal of this work is to demonstrate molecular severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monitoring in bulk floor dust and related samples as a proof of concept of a noninvasive environmental surveillance methodology for coronavirus disease 2019 (COVID-19) and potentially other viral diseases. Surface swab, passive sampler, and bulk floor dust samples were collected from the rooms of individuals positive for COVID-19, and SARS-CoV-2 was measured with quantitative reverse transcription-PCR (RT-qPCR) and two digital PCR (dPCR) methods. Bulk dust samples had a geometric mean concentration of 163 copies/mg of dust and ranged from nondetects to 23,049 copies/mg of dust detected using droplet digital PCR (ddPCR). An average of 89% of bulk dust samples were positive for the virus by the detection methods compared to 55% of surface swabs and fewer on the passive sampler (19% carpet, 29% polystyrene). In bulk dust, SARS-CoV-2 was detected in 76%, 93%, and 97% of samples measured by qPCR, chip-based dPCR, and droplet dPCR, respectively. Detectable viral RNA in the bulk vacuum bags did not measurably decay over 4 weeks, despite the application of a disinfectant before room cleaning. Future monitoring efforts should further evaluate RNA persistence and heterogeneity in dust. This study did not measure virus infectivity in dust or potential transmission associated with dust. Overall, this work demonstrates that bulk floor dust is a potentially useful matrix for long-term monitoring of viral disease in high-risk populations and buildings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.